MENU
+Compare
CGC
Stock ticker: NASDAQ
AS OF
Nov 21, 12:40 PM (EDT)
Price
$1.03
Change
+$0.02 (+1.98%)
Capitalization
350.87M

CGC stock forecast, quote, news & analysis

Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others... Show more

CGC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CGC showed earnings on November 07, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for CGC with price predictions
Nov 20, 2025

Momentum Indicator for CGC turns negative, indicating new downward trend

CGC saw its Momentum Indicator move below the 0 level on October 21, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned negative. In of the 75 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

CGC moved below its 50-day moving average on October 16, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CGC crossed bearishly below the 50-day moving average on October 21, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for CGC moved below the 200-day moving average on November 10, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CGC entered a downward trend on November 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CGC's RSI Oscillator exited the oversold zone, of 52 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CGC advanced for three days, in of 203 cases, the price rose further within the following month. The odds of a continued upward trend are .

CGC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.657) is normal, around the industry mean (17.079). P/E Ratio (0.000) is within average values for comparable stocks, (71.781). CGC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.902). CGC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.922) is also within normal values, averaging (55.540).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.06B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -3%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 27%. RGTLF experienced the highest price growth at 66%, while TSNDF experienced the biggest fall at -38%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -14%. For the same stocks of the Industry, the average monthly volume growth was 7% and the average quarterly volume growth was 27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 62
Price Growth Rating: 60
SMR Rating: 79
Profit Risk Rating: 90
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
CGC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a producer of medical marijuana

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Agricultural Commodities Or Milling
Address
1 Hershey Drive
Phone
+1 855 558-9333
Employees
1621
Web
https://www.canopygrowth.com